Back to top
more

Amgen (AMGN)

(Delayed Data from NSDQ)

$301.94 USD

301.94
2,307,992

+5.06 (1.70%)

Updated Aug 4, 2025 04:00 PM ET

After-Market: $302.01 +0.07 (0.02%) 7:48 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth D Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 42% (143 out of 246)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Thousand Oaks, CA-based Amgen is one of the biggest biotech companies in the world, with a strong presence in the oncology/hematology, cardiovascular disease, neuroscience, inflammation, bone health and nephrology markets. The company used advances in cellular and molecular biology to develop two of the biotech industry’s earliest and most successful drugs, Epogen (anemia) and Neupogen (white blood cell stimulant). Amgen successfully launched two next-generation products, Aranesp and Neulasta. Meanwhile, the acquisition of Immunex Corporation gave Amgen access to the multi-blockbuster drug, Enbrel. However, all these older drugs are facing declining sales due to biosimilar or branded competition, which is being somewhat offset by its newer blockbuster drugs like Prolia/Xgeva

Zacks Equity Research

Amgen (AMGN) Surpasses Market Returns: Some Facts Worth Knowing

by Zacks Equity Research

Amgen (AMGN) reachead $265.44 at the closing of the latest trading day, reflecting a +1.7% change compared to its last close.

Sheraz Mian headshot

Top Research Reports for Amgen, ServiceNow & RTX

by Sheraz Mian

Today's Research Daily features new research reports on 16 major stocks, including Amgen Inc. (AMGN), ServiceNow, Inc. (NOW) and RTX Corporation (RTX).

Abhinab Dasgupta headshot

Take the Zacks Approach to Beat the Market: Shopify, Caterpillar, Amgen in Focus

by Abhinab Dasgupta

Our time-tested methodologies were at work to help investors navigate the market well last week. Here are some of our key performance data from the past three months.

Kinjel Shah headshot

3 Stocks to Focus on as Demand for Obesity Drugs Booms

by Kinjel Shah

With the obesity market gaining popularity, analysts are expecting sales to increase. Pharma companies are rushing to enter the market

Zacks Equity Research

Is iShares Biotechnology ETF (IBB) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for IBB

Zacks Equity Research

Amgen (AMGN) Outpaces Stock Market Gains: What You Should Know

by Zacks Equity Research

In the latest trading session, Amgen (AMGN) closed at $270.82, marking a +0.68% move from the previous day.

Zacks Equity Research

Amgen (AMGN) Stock Sinks As Market Gains: What You Should Know

by Zacks Equity Research

In the latest trading session, Amgen (AMGN) closed at $268.98, marking a -0.02% move from the previous day.

Zacks Equity Research

Coherus (CHRS) Gets CRL for Udenyca Onbody, Shares Down

by Zacks Equity Research

Coherus (CHRS) gets CRL for the biologics license application supplement for Udenyca Onbody, an on-body injector presentation of Udenyca.

Zacks Equity Research

Amgen Inc. (AMGN) Is a Trending Stock: Facts to Know Before Betting on It

by Zacks Equity Research

Amgen (AMGN) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Abhinab Dasgupta headshot

Beat the Market Like Zacks: Elementis, Novo Nordisk, Amgen in Focus

by Abhinab Dasgupta

Last week, our time-tested methodologies served investors well in navigating the market. Check out some of our achievements from the past three months.

Zacks Equity Research

Should You Invest in the Invesco Pharmaceuticals ETF (PJP)?

by Zacks Equity Research

Sector ETF report for PJP

Zacks Equity Research

Amgen (AMGN) Stock Moves -0.76%: What You Should Know

by Zacks Equity Research

In the latest trading session, Amgen (AMGN) closed at $269.41, marking a -0.76% move from the previous day.

Zacks Equity Research

Should You Invest in the iShares Biotechnology ETF (IBB)?

by Zacks Equity Research

Sector ETF report for IBB

Abhinab Dasgupta headshot

Beat the Market the Zacks Way: Automatic Data Processing, Casey's, Paysafe in Focus

by Abhinab Dasgupta

Our time-tested methodologies were at work to help investors navigate the market well last week. Here are some of our key performance data from the past three months.

Zacks Equity Research

Amgen (AMGN) Outpaces Stock Market Gains: What You Should Know

by Zacks Equity Research

In the latest trading session, Amgen (AMGN) closed at $262.30, marking a +1.97% move from the previous day.

Zacks Equity Research

AbbVie's (ABBV) Skyrizi Crohn's Disease Study Meets Goals

by Zacks Equity Research

AbbVie's (ABBV) Skyrizi met both primary endpoints of non-inferiority for clinical remission at week 24 and superiority of endoscopic remission at week 48 versus J&J's Stelara in a head-to-head study.

Zacks Equity Research

Investors Heavily Search Amgen Inc. (AMGN): Here is What You Need to Know

by Zacks Equity Research

Amgen (AMGN) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Abhinab Dasgupta headshot

Take the Zacks Approach to Beat the Market: Shopify, Novo Nordisk, Amgen in Focus

by Abhinab Dasgupta

Last week, our time-tested methodologies served investors well in navigating the market. Check out some of our achievements from the past three months.

Zacks Equity Research

Amgen (AMGN) Outpaces Stock Market Gains: What You Should Know

by Zacks Equity Research

In the latest trading session, Amgen (AMGN) closed at $259.43, marking a +1.98% move from the previous day.

Zacks Equity Research

Biotech Stock Roundup: MRNA's Vaccine Update, AMGN & HZNP Clear FTC Lawsuit & More

by Zacks Equity Research

Pipeline and regulatory updates from (MRNA) and Amgen (AMGN) are in focus in the biotech sector.

Zacks Equity Research

Amgen (AMGN) Stock Outperforms Industry YTD: Here's Why

by Zacks Equity Research

Amgen (AMGN) expects strong sales growth of products like Tezspire, Evenity and Repatha to be offset by lower revenues from oncology biosimilars and Enbrel.

Abhinab Dasgupta headshot

Beat the Market the Zacks Way: NVIDIA, Novo Nordisk, Matson in Focus

by Abhinab Dasgupta

Our time-tested methodologies were at work to help investors navigate the market well last week. Here are some of our key performance data from the past three months.

Zacks Equity Research

FTC Allows Amgen (AMGN) to Proceed With $28B Horizon Buyout

by Zacks Equity Research

Per the settlement terms, Amgen (AMGN) is prohibited from bundling its products with Horizon's Tepezza or Krystexxa. Amgen expects to complete the Horizon acquisition before 2023-end.

Zacks Equity Research

Amgen (AMGN) is a Top-Ranked Momentum Stock: Should You Buy?

by Zacks Equity Research

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Zacks Equity Research

Here is What to Know Beyond Why Amgen Inc. (AMGN) is a Trending Stock

by Zacks Equity Research

Amgen (AMGN) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.